TopicalDosed ingredient Cosmetic cross-reference

Octocrylene

CAS 6197-30-4

Octocrylene (CAS 6197-30-4) is a Phase 4 pharmaceutical compound with 3 bioactivity targets and 95 adverse event associations.

SOURCE NLM DailyMed
Label records
6
SOURCE EMBL-EBI ChEMBL
Bioactivity
3
SOURCE DrugCentral / FAERS
Adverse signals
95
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Octocrylene
CAS Number
6197-30-4
UNII
5A68WGF6WM
InChIKey
FMJSMJQBSVNSBF-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1201147
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural producttopical
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1201147 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DailyMed SPL XML 6 label rows

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
Neutrogena Ultra Sheer Dry Touch Sunscreen Broad Spectrum SPF 70 OCTOCRYLENE
5A68WGF6WM
 OCTOCRYLENE 20260505
SURFACE SUN SPF 50 DRY TOUCH Fragrance Free OCTOCRYLENE
5A68WGF6WM
 OCTOCRYLENE 20260505
SURFACE SUN SPF 50 DRY TOUCH Fragrance Free OCTOCRYLENE
5A68WGF6WM
 OCTOCRYLENE 20260505
SURFACE SUN SPF30 DRY TOUCH Fragrance Free OCTOCRYLENE
5A68WGF6WM
 OCTOCRYLENE 20260505
THANKYOU FARMER Sun Project Moisture Sun OCTOCRYLENE
5A68WGF6WM
 OCTOCRYLENE 20260505
No 7 Prime Forever SPF 50 Primer OCTOCRYLENE
5A68WGF6WM
 OCTOCRYLENE 20260430
SOURCE ChEMBL 36 activities + assays 3 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 31553.247619047615 nM 38 -
- AC50 12614.199999999999 nM 3 -
- IC50 6644.745 nM 2 -
SOURCE DrugCentral 2023 / FAERS disproportionality 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Macular degeneration 264 796.543 10025409
Therapy interrupted 140 279.378 10066377
Chronic sinusitis 94 240.793 10009137
Paraesthesia oral 98 217.886 10057372
Procedural pain 98 208.586 10064882
Therapy cessation 100 161.985 10065154
Death 383 151.902 10011906
Vaginal flatulence 39 124.652 10064227
Body tinea 33 116.543 10005913
Female genital tract fistula 42 105.287 10061149
Radiculopathy 44 94.82 10037779
Proctitis 40 94.503 10036774
Infection susceptibility increased 33 92.269 10021866
Inhibitory drug interaction 33 89.751 10068071
Vaginal discharge 39 87.841 10046901
Removal of foreign body 15 85.86 10062102
Surgery 68 83.208 10042609
Therapeutic product effect incomplete 127 83.085 10082200
Cardiac arrest 126 80.418 10007515
Dyspepsia 104 73.509 10013946
Anal inflammation 21 69.782 10050247
Glucose tolerance impaired 33 66.594 10018429
Poor quality sleep 47 64.963 10062519
Methaemoglobinaemia 28 64.169 10027496
Drug ineffective 464 63.735 10013709
Foetal death 35 63.197 10055690
SARS-CoV-2 test negative 18 58.796 10084273
Local anaesthetic systemic toxicity 17 56.964 10082534
Impaired quality of life 37 55.686 10076936
Hospitalisation 92 55.38 10054112
Bone density decreased 34 51.818 10049470
Purpura 36 49.984 10037549
Colitis ulcerative 48 49.29 10009900
Product packaging confusion 15 46.827 10074776
Appendicolith 24 44.587 10074458
Oral candidiasis 41 44.537 10030963
Impaired work ability 35 43.907 10052302
Hyperlipidaemia 39 42.159 10062060
Tracheal deviation 9 42.022 10044287
Frequent bowel movements 40 40.835 10017367
Foreign body 17 40.558 10070245
Ventricular fibrillation 39 40.525 10047290
Pyrexia 253 40.122 10037660
Anaphylactic shock 41 40.03 10002199
Skin disorder 43 39.797 10040831
Constipation 141 37.574 10010774
Proctalgia 24 36.972 10036772
Accident 23 36.072 10000369
Phrenic nerve paralysis 9 36.062 10064964
Oral herpes 36 36.047 10067152

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Octocrylene used for in pharmaceutical contexts?

Octocrylene (CAS 6197-30-4) appears in DailyMed active-ingredient label rows, including Neutrogena Ultra Sheer Dry Touch Sunscreen Broad Spectrum SPF 70, SURFACE SUN SPF 50 DRY TOUCH Fragrance Free, SURFACE SUN SPF30 DRY TOUCH Fragrance Free.

What are the known adverse events for Octocrylene?

Octocrylene has 95 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Macular degeneration, Therapy interrupted, Chronic sinusitis, Paraesthesia oral, Procedural pain. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Octocrylene also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Octocrylene with EU status "permitted".

What clinical phase is Octocrylene in?

Octocrylene is rendered with ChEMBL max phase 4 (approved).